Did you know there’s a global market leader from Singapore? It operates in a niche market, producing fluorescence imaging solutions that are essential in medical surgeries.

UltragreenAI has hit the investment radar this week, as it is potentially undervalued at this point with a huge potential upside. 

Let’s take a look at the investment thesis of this company and whether it presents an attractive opportunity.

UltragreenAI’s share price had corrected in the past two months. It declined by 33.8% from its peak of US$1.86 in February 2026 to US$1.39 as of 29 April 2026. Share price is now below its IPO price of US$1.45.

It is currently trading at a price-to-earnings (PER) and price-to-book ratios of 20.2 times and 4.9 times, respectively. Both ratios are lower than the packaged software industry averages of 31.5 times and 5.2 times.

According to Shareinvestor’s discounted cash flow analysis, the stock could be undervalued by up to 50% with conservative assumptions of 5% annual growth in cash flow and a 5% discount rate.

UltragreenAI commands most of the fluorescence-guided surgery (FGS) market, with close to 70% in market share. It has a leading position in its core markets of the United States and Europe.

It sells Indocyanine Green (ICG) to most of its clients in the healthcare sector, where it provides imaging solutions to surgeons that increase precision. As most of the industry uses ICG, prospects are expected to be bright. The Global ICG market is projected to double from US$173 million in 2024 to US$335 million by 2030.

In just 3 years, the company has almost tripled its revenue from US$49.2 million in 2022 to US$142.4 million in 2025. Most of this growth was driven by both volume and selling price increases.

With higher volume and selling prices, UltragreenAI has been able to deliver higher operational margins over the years. EBITDA margin rose from 56.2% in 2022 to 62.8% in 2025.

In its November 2025 listing, UltragreenAI raised US$162.5 million in proceeds. That has boosted its cash position to US$176.1 million as of December 2025.

It intends to use US$55 million to develop its ICG product, IC-Flow Imaging platform and its Ultragreen Data Platform. It has also earmarked US$22 million for expansion into new countries in the Asia Pacific, Europe, the Middle East and Africa regions.

Furthermore, according to Frost & Sullivan, the penetration rate is below 25% in the U.S. for procedures such as cholecystectomy, colectomy and breast reconstruction. 

Analysts in the market are bullish on the stock. The average target price is set at US$1.98 with a potential upside of +41.7%.

They are forecasting a 24.7% growth in their revenue in 2026, coupled with a similar EBITDA margin of 62.2%. This is consistent with UltragreenAI’s guidance of a revenue range of US$170 million to US$190 million.

The recent share price dip below its IPO price suggests an undervalued opportunity for a global market leader in the ICG industry. UltragreenAI’s dominant market position is a big selling point for a fast-growing niche market that could double by 2030.